<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825440</article-id>
    <article-id pub-id-type="pmid">35947748</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac677</article-id>
    <article-id pub-id-type="publisher-id">gkac677</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SUMMER: a Mendelian randomization interactive server to systematically evaluate the causal effects of risk factors and circulating biomarkers on pan-cancer survival</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Xin</surname>
          <given-names>Junyi</given-names>
        </name>
        <aff><institution>Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gu</surname>
          <given-names>Dongying</given-names>
        </name>
        <aff><institution>Department of Oncology, Nanjing First Hospital, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Silu</given-names>
        </name>
        <aff><institution>Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <aff><institution>Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ben</surname>
          <given-names>Shuai</given-names>
        </name>
        <aff><institution>Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <aff><institution>Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Huiqin</given-names>
        </name>
        <aff><institution>Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <aff><institution>Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6730-9251</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Zhengdong</given-names>
        </name>
        <aff><institution>Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <aff><institution>Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2733-6490</contrib-id>
        <name>
          <surname>Du</surname>
          <given-names>Mulong</given-names>
        </name>
        <!--drdumulong@njmu.edu.cn-->
        <aff><institution>Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4996-958X</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Meilin</given-names>
        </name>
        <!--mwang@njmu.edu.cn-->
        <aff><institution>Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <aff><institution>Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University</institution>, Nanjing, <country country="CN">China</country></aff>
        <aff><institution>The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University</institution>, Suzhou, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 25 8686 8423; Fax: +86 25 8686 8499; Email: <email>mwang@njmu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Mulong Du. Email: <email>drdumulong@njmu.edu.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first three authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-08-10">
      <day>10</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>10</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D1160</fpage>
    <lpage>D1167</lpage>
    <history>
      <date date-type="accepted">
        <day>26</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>18</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>20</day>
        <month>6</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac677.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Genome-wide association studies (GWASs) underlying case-control design have uncovered hundreds of genetic loci involved in tumorigenesis and provided rich resources for identifying risk factors and biomarkers associated with cancer susceptibility. However, the application of GWAS in determining the genetic architecture of cancer survival remains unestablished. Here, we systematically evaluated genetic effects at the genome-wide level on cancer survival that included overall survival (OS) and cancer-specific survival (CSS), leveraging data deposited in the UK Biobank cohort of a total of 19 628 incident patients across 17 cancer types. Furthermore, we assessed the causal effects of risk factors and circulating biomarkers on cancer prognosis via a Mendelian randomization (MR) analytic framework, which integrated cancer survival GWAS dataset, along with phenome-wide association study (PheWAS) and blood genome-wide gene expression/DNA methylation quantitative trait loci (eQTL/meQTL) datasets. On average, more than 10 traits, 700 genes, and 4,500 CpG sites were prone to cancer prognosis. Finally, we developed a user-friendly online database, <bold><underline>SU</underline></bold>rvival related cancer <bold><underline>M</underline></bold>ulti-omics database via <bold><underline>ME</underline></bold>ndelian <bold><underline>R</underline></bold>andomization (SUMMER; <ext-link xlink:href="http://njmu-edu.cn:3838/SUMMER/" ext-link-type="uri">http://njmu-edu.cn:3838/SUMMER/</ext-link>), to help users query, browse, and download cancer survival results. In conclusion, SUMMER provides an important resource to assist the research community in understanding the genetic mechanisms of cancer survival.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>82173601</award-id>
        <award-id>82173603</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Jiangsu Higher Education Institutions</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Cancer ranks as a leading cause of death and remains an important barrier to increasing life expectancy worldwide (<xref rid="B1" ref-type="bibr">1</xref>). According to global cancer statistics, there was an estimated 10.0 million cancer deaths occurred in 2020 (<xref rid="B2" ref-type="bibr">2</xref>). It is noteworthy that survival probability is an important index that can be used to directly measure the tumor burden of patients, and accurate survival estimate can provide valuable insights into the precision therapy of cancer patients (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). Thus, there is an urgent need to identify risk factors and biomarkers that can be used in the clinic to predict cancer prognosis early.</p>
    <p>Currently, genome-wide association studies (GWASs) have uncovered hundreds of genetic loci involved in cancer susceptibility (<xref rid="B5" ref-type="bibr">5–7</xref>), but their application in identifying the genetic architecture of cancer survival has not been widely established. GWASs provide a way to better understand biological mechanisms linking potential risk factors or biomarkers to diseases (<xref rid="B8" ref-type="bibr">8</xref>). Mendelian randomization (MR) has become an important statistical approach routinely used in ‘post-GWAS’ analyses (<xref rid="B9" ref-type="bibr">9</xref>); it is a well-known causal inference method that uses single nucleotide polymorphisms (SNPs) as instrumental variables (IVs, i.e. genetic predictors), and has been widely used to assess the causal association between exposures [e.g. body mass index (BMI) and smoking] and outcomes (e.g. cancer survival) (<xref rid="B10" ref-type="bibr">10–12</xref>).</p>
    <p>Therefore, we aimed to construct an online pan-cancer survival database that included available survival GWAS summary statistics, followed by causal risk factors and biomarkers involving cancer survival obtained via MR analysis. To meet this goal, we conducted a two-stage design in this study (Figure <xref rid="F1" ref-type="fig">1</xref>) as follows:</p>
    <list list-type="roman-lower">
      <list-item>
        <p>Construction of pan-cancer survival GWAS dataset: We aimed to systematically evaluate the effects of genome-wide genetic variants on cancer survival that included overall survival (OS) and cancer-specific survival (CSS), leveraging a total of 19,628 incident patients across 17 cancer types derived from the UK Biobank cohort.</p>
      </list-item>
      <list-item>
        <p>Integrative analysis to identify cancer prognostic risk factors and circulating biomarkers: We aimed to evaluate the causal effects of risk factors and circulating biomarkers on cancer prognosis via a comprehensive MR approach that integrated pan-cancer survival GWAS dataset, along with phenome-wide association study (PheWAS) and blood gene expression/DNA methylation quantitative trait loci (eQTL/meQTL) datasets.</p>
      </list-item>
    </list>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Summary of the study design. Note: GWAS, genome-wide association study; PheWAS, phenome-wide association study; eQTL, expression quantitative trait loci; meQTL, methylation quantitative trait loci.</p>
      </caption>
      <graphic xlink:href="gkac677fig1" position="float"/>
    </fig>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Construction of pan-cancer survival GWAS dataset</title>
      <sec id="SEC2-1-1">
        <title>UK Biobank cohort</title>
        <p>The UK Biobank cohort was a prospective, population-based study that recruited 502 528 adults aged 40–69 years from the general population between 2006 and 2010 (<xref rid="B13" ref-type="bibr">13</xref>). Participants visited one of 22 assessment centers across England, Scotland and Wales, where they completed touchscreen and nurse-led questionnaires, and provided biological samples. The study protocol and information about data access are available online (<ext-link xlink:href="https://www.ukbiobank.ac.uk/" ext-link-type="uri">https://www.ukbiobank.ac.uk/</ext-link>). The current study was conducted using the UK Biobank Resource under Application #45611.</p>
        <p>A total of 355 543 participants remained for analysis after the following individual-level quality control (QC) process: (i) excluded individuals with prevalent cancer (except non-melanoma skin cancer, based on the International Classification of Diseases, 10th revision [ICD-10, C44]) at baseline; (ii) excluded individuals of sex discordance; (iii) excluded outliers for genotype missingness or excess heterozygosity; (iv) retained unrelated participants; (v) restricted to ‘white British’ individuals of European ancestry and (vi) removed individuals who decided not to participate in this program. The follow-up time of cancer survival was calculated from cancer diagnosis (defined by ICD-10 codes (<xref rid="B14" ref-type="bibr">14</xref>)) to death or the last follow-up (14 February 2018). We determined whether an individual died of a specific cancer by considering the ICD-10 codes listed as the primary cause of death.</p>
      </sec>
      <sec id="SEC2-1-2">
        <title>Pan-cancer survival GWAS analysis</title>
        <p>All samples derived from UK Biobank were genotyped using the UK BiLEVE Axiom Array or UK Biobank Axiom Array by Affymetrix (<xref rid="B15" ref-type="bibr">15</xref>). The genotyping data were imputed using SHAPEIT3 and IMPUTE3 based on the reference panels of Haplotype Reference Consortium (HRC), UK10K and 1000 Genomes Project (Phase 3). The study protocol and information about data access are available online (<ext-link xlink:href="http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UKBiobank-Protocol.pdf" ext-link-type="uri">http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UKBiobank-Protocol.pdf</ext-link>).</p>
        <p>We kept variants based on a strict QC process consisting of (i) SNPs located within autosomal chromosomes; (ii) imputation info score ≥0.3; (iii) minor allele frequency (MAF) ≥0.01; (iv) call rate ≥95% and (v) Hardy–Weinberg Equilibrium (HWE) <italic toggle="yes">P</italic> value ≥1 × 10<sup>–6</sup>. Subsequently, the Cox proportional hazards regression analysis in an additive genetic model was applied to evaluate the association between each SNP and cancer survival that included OS and CSS, with adjustment for sex, age at diagnosis, BMI, smoking status, drinking status, and the top 10 principal components of population stratification when approximate. The genomic control inflation factor was used to assess the population stratification issues, and we determined cancer survival-associated loci at a suggestive genome-wide significance threshold of <italic toggle="yes">P</italic>-value ≤1 × 10<sup>–6</sup>.</p>
      </sec>
    </sec>
    <sec id="SEC2-2">
      <title>Identification of cancer survival-associated risk factors</title>
      <sec id="SEC2-2-1">
        <title>PheWAS dataset</title>
        <p>The GWAS summary statistics in the PheWAS dataset were accessed through the IEU Open GWAS project (<ext-link xlink:href="https://gwas.mrcieu.ac.uk/" ext-link-type="uri">https://gwas.mrcieu.ac.uk/</ext-link>) and were extracted with the R package <italic toggle="yes">TwoSampleMR</italic> (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>).</p>
        <p>Based on a curated list of traits analyzed previously with an MR framework (<xref rid="B18" ref-type="bibr">18</xref>) and a strict QC process consisting of (i) limited in European population and (ii) with ≥3 independent [linkage disequilibrium (LD) <italic toggle="yes">r<sup>2</sup></italic> &lt; 0.01] genetic instruments (defined by SNPs with <italic toggle="yes">P</italic>-value ≤ 5 × 10<sup>–8</sup>), we included a total of 150 traits in this study, which spanned the categories of anthropometric, autoimmune/inflammatory, behavioural, cardiovascular, ICD10 codes, miscellaneous, non-cancer illness, and psychiatric/neurological traits (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>MR analysis</title>
        <p>MR is a causal inference method, that uses germline genetic variants (i.e. SNPs) as genetic instruments to estimate and test for the causative effect of an exposure variable on an outcome (<xref rid="B10" ref-type="bibr">10</xref>).</p>
        <p>Here, we used the R package <italic toggle="yes">TwoSampleMR</italic> to apply multiple MR methods in the phenotype-survival association analysis, including inverse variance weighted (IVW), weighted median, penalized weighted median, and MR Egger methods. In addition, the heterogeneity test was used to assess whether a genetic variant's effect on outcome was proportional to its effect on exposure, and the MR-Egger intercept test was fitted to evaluate the presence of horizontal pleiotropy (<xref rid="B19" ref-type="bibr">19</xref>). The suggestive evidence between phenotypes and cancer survival was identified when three nominal thresholds were met, including <italic toggle="yes">P</italic>-value for IVW analysis ≤0.05, <italic toggle="yes">P</italic>-value for egger intercept &gt;0.05, and <italic toggle="yes">P</italic>-value for heterogeneity &gt;0.05.</p>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>Identification of cancer survival-associated circulating biomarkers</title>
      <sec id="SEC2-3-1">
        <title>eQTL and meQTL datasets</title>
        <p>We obtained an eQTL dataset from the eQTLGen consortium (<ext-link xlink:href="https://eqtlgen.org/" ext-link-type="uri">https://eqtlgen.org/</ext-link>), that incorporated 37 datasets, with a total of 31 684 blood samples with the majority in European ancestry. The detailed methods were described in previous studies (<xref rid="B20" ref-type="bibr">20</xref>). In addition, the meQTL dataset was derived from Hannon <italic toggle="yes">et al.</italic>’s study, with a total of 1175 blood samples of European ancestry for subsequent analysis (<xref rid="B21" ref-type="bibr">21</xref>).</p>
      </sec>
      <sec id="SEC2-3-2">
        <title>Summary-data-based MR (SMR) analysis</title>
        <p>Similar to phenotype-based MR analysis, the associations between biomarkers and cancer survival were evaluated using the SMR analytic framework with default settings (–peqtl-smr 5E-08 –peqtl-heidi 1.57E-03 –<italic toggle="yes">cis</italic>-wind 2000) by integrating the cancer survival GWAS summary statistics data with <italic toggle="yes">cis</italic>-eQTL and <italic toggle="yes">cis</italic>-meQTL results (i.e. with a window of 2000 kb to select SNPs centred around the target biomarker) (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>). The genotype data from the European population of the 1000 Genomes Project Phase 3 were used for the LD estimation. The suggestive colocalized signals were determined at a nominal threshold of <italic toggle="yes">P</italic>-value for SMR analysis ≤0.05 and <italic toggle="yes">P</italic>-value for HEIDI (i.e. heterogeneity test in dependent instruments) &gt;0.05.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>RESULTS</title>
    <sec id="SEC3-1">
      <title>Summary of cancer survival GWAS dataset</title>
      <p>In the UK Biobank cohort, 19 628 of 355 543 individuals were newly diagnosed with one or more of 17 cancer types, ranging from 179 thyroid cancer cases to 4882 prostate cancer cases (Table <xref rid="tbl1" ref-type="table">1</xref>). During a median follow-up time of 4.06 years after the clinical diagnosis, the proportion of all-cause deaths ranged from 7.33% (319/4350, breast cancer) to 90.91% (460/506, pancreatic cancer), and the proportion of cancer-specific deaths ranged from 3.35% (6/179, thyroid cancer) to 84.13% (334/397, brain cancer; Table <xref rid="tbl1" ref-type="table">1</xref>).</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Basic characteristics of incident cancer cases in the UK Biobank cohort</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th colspan="2" align="center" rowspan="1">Gender (%)</th>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th colspan="2" align="center" rowspan="1">Death (%)</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">Cancer type</th>
              <th rowspan="1" colspan="1">Cases</th>
              <th rowspan="1" colspan="1">Median follow-up time (months)</th>
              <th rowspan="1" colspan="1">Male</th>
              <th rowspan="1" colspan="1">Female</th>
              <th rowspan="1" colspan="1">Age<sup>a</sup> (mean ± SD)</th>
              <th rowspan="1" colspan="1">BMI (mean ± SD)</th>
              <th rowspan="1" colspan="1">All-cause</th>
              <th rowspan="1" colspan="1">Cancer-specific</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Bladder cancer</td>
              <td rowspan="1" colspan="1">526</td>
              <td rowspan="1" colspan="1">49.63</td>
              <td rowspan="1" colspan="1">426 (80.99)</td>
              <td rowspan="1" colspan="1">100 (19.01)</td>
              <td rowspan="1" colspan="1">67.11 ± 5.61</td>
              <td rowspan="1" colspan="1">28.25 ± 4.34</td>
              <td rowspan="1" colspan="1">170 (32.32)</td>
              <td rowspan="1" colspan="1">113 (21.48)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Brain cancer</td>
              <td rowspan="1" colspan="1">397</td>
              <td rowspan="1" colspan="1">8.83</td>
              <td rowspan="1" colspan="1">246 (61.96)</td>
              <td rowspan="1" colspan="1">151 (38.04)</td>
              <td rowspan="1" colspan="1">64.24 ± 7.04</td>
              <td rowspan="1" colspan="1">27.65 ± 4.76</td>
              <td rowspan="1" colspan="1">354 (89.17)</td>
              <td rowspan="1" colspan="1">334 (84.13)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">4350</td>
              <td rowspan="1" colspan="1">62.13</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">4350 (100)</td>
              <td rowspan="1" colspan="1">61.84 ± 7.78</td>
              <td rowspan="1" colspan="1">27.46 ± 5.10</td>
              <td rowspan="1" colspan="1">319 (7.33)</td>
              <td rowspan="1" colspan="1">233 (5.36)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1">2621</td>
              <td rowspan="1" colspan="1">48.57</td>
              <td rowspan="1" colspan="1">1555 (59.33)</td>
              <td rowspan="1" colspan="1">1066 (40.67)</td>
              <td rowspan="1" colspan="1">65.25 ± 6.53</td>
              <td rowspan="1" colspan="1">27.94 ± 4.59</td>
              <td rowspan="1" colspan="1">779 (29.72)</td>
              <td rowspan="1" colspan="1">569 (21.71)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Corpus Uteri</td>
              <td rowspan="1" colspan="1">698</td>
              <td rowspan="1" colspan="1">57.58</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">698 (100)</td>
              <td rowspan="1" colspan="1">64.17 ± 6.29</td>
              <td rowspan="1" colspan="1">30.30 ± 6.95</td>
              <td rowspan="1" colspan="1">105 (15.04)</td>
              <td rowspan="1" colspan="1">78 (11.17)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophagus cancer</td>
              <td rowspan="1" colspan="1">460</td>
              <td rowspan="1" colspan="1">19.57</td>
              <td rowspan="1" colspan="1">344 (74.78)</td>
              <td rowspan="1" colspan="1">116 (25.22)</td>
              <td rowspan="1" colspan="1">66.42 ± 5.81</td>
              <td rowspan="1" colspan="1">28.63 ± 5.61</td>
              <td rowspan="1" colspan="1">296 (64.35)</td>
              <td rowspan="1" colspan="1">255 (55.43)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gastric cancer</td>
              <td rowspan="1" colspan="1">303</td>
              <td rowspan="1" colspan="1">14.60</td>
              <td rowspan="1" colspan="1">222 (73.27)</td>
              <td rowspan="1" colspan="1">81 (26.73)</td>
              <td rowspan="1" colspan="1">66.30 ± 6.63</td>
              <td rowspan="1" colspan="1">28.68 ± 4.91</td>
              <td rowspan="1" colspan="1">220 (72.61)</td>
              <td rowspan="1" colspan="1">141 (46.53)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung cancer</td>
              <td rowspan="1" colspan="1">1700</td>
              <td rowspan="1" colspan="1">11.47</td>
              <td rowspan="1" colspan="1">945 (55.59)</td>
              <td rowspan="1" colspan="1">755 (44.41)</td>
              <td rowspan="1" colspan="1">66.65 ± 5.99</td>
              <td rowspan="1" colspan="1">27.46 ± 4.73</td>
              <td rowspan="1" colspan="1">1,287 (75.71)</td>
              <td rowspan="1" colspan="1">1,113 (65.47)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lymphoid Leukaemia</td>
              <td rowspan="1" colspan="1">350</td>
              <td rowspan="1" colspan="1">51.90</td>
              <td rowspan="1" colspan="1">209 (59.71)</td>
              <td rowspan="1" colspan="1">141 (40.29)</td>
              <td rowspan="1" colspan="1">65.42 ± 6.04</td>
              <td rowspan="1" colspan="1">27.96 ± 5.11</td>
              <td rowspan="1" colspan="1">58 (16.57)</td>
              <td rowspan="1" colspan="1">26 (7.43)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Multiple Myeloma</td>
              <td rowspan="1" colspan="1">355</td>
              <td rowspan="1" colspan="1">43.10</td>
              <td rowspan="1" colspan="1">207 (58.31)</td>
              <td rowspan="1" colspan="1">148 (41.69)</td>
              <td rowspan="1" colspan="1">65.86 ± 6.78</td>
              <td rowspan="1" colspan="1">27.79 ± 4.54</td>
              <td rowspan="1" colspan="1">122 (34.37)</td>
              <td rowspan="1" colspan="1">90 (25.35)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Oral and pharynx cancer</td>
              <td rowspan="1" colspan="1">458</td>
              <td rowspan="1" colspan="1">50.45</td>
              <td rowspan="1" colspan="1">312 (68.12)</td>
              <td rowspan="1" colspan="1">146 (31.88)</td>
              <td rowspan="1" colspan="1">62.80 ± 6.94</td>
              <td rowspan="1" colspan="1">27.27 ± 4.92</td>
              <td rowspan="1" colspan="1">120 (26.2)</td>
              <td rowspan="1" colspan="1">71 (15.5)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Ovarian cancer</td>
              <td rowspan="1" colspan="1">437</td>
              <td rowspan="1" colspan="1">40.33</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">437 (100)</td>
              <td rowspan="1" colspan="1">63.65 ± 7.26</td>
              <td rowspan="1" colspan="1">27.29 ± 4.86</td>
              <td rowspan="1" colspan="1">201 (46)</td>
              <td rowspan="1" colspan="1">177 (40.5)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic cancer</td>
              <td rowspan="1" colspan="1">506</td>
              <td rowspan="1" colspan="1">5.35</td>
              <td rowspan="1" colspan="1">274 (54.15)</td>
              <td rowspan="1" colspan="1">232 (45.85)</td>
              <td rowspan="1" colspan="1">66.27 ± 6.29</td>
              <td rowspan="1" colspan="1">28.21 ± 5.02</td>
              <td rowspan="1" colspan="1">460 (90.91)</td>
              <td rowspan="1" colspan="1">422 (83.4)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate cancer</td>
              <td rowspan="1" colspan="1">4882</td>
              <td rowspan="1" colspan="1">57.93</td>
              <td rowspan="1" colspan="1">4,882 (100)</td>
              <td rowspan="1" colspan="1">0 (0)</td>
              <td rowspan="1" colspan="1">66.77 ± 5.32</td>
              <td rowspan="1" colspan="1">27.55 ± 3.83</td>
              <td rowspan="1" colspan="1">460 (9.42)</td>
              <td rowspan="1" colspan="1">258 (5.28)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Renal cancer</td>
              <td rowspan="1" colspan="1">649</td>
              <td rowspan="1" colspan="1">44.40</td>
              <td rowspan="1" colspan="1">425 (65.49)</td>
              <td rowspan="1" colspan="1">224 (34.51)</td>
              <td rowspan="1" colspan="1">65.21 ± 6.38</td>
              <td rowspan="1" colspan="1">29.18 ± 5.26</td>
              <td rowspan="1" colspan="1">209 (32.2)</td>
              <td rowspan="1" colspan="1">147 (22.65)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Skin Melanoma</td>
              <td rowspan="1" colspan="1">1402</td>
              <td rowspan="1" colspan="1">56.27</td>
              <td rowspan="1" colspan="1">717 (51.14)</td>
              <td rowspan="1" colspan="1">685 (48.86)</td>
              <td rowspan="1" colspan="1">63.39 ± 7.68</td>
              <td rowspan="1" colspan="1">27.58 ± 4.48</td>
              <td rowspan="1" colspan="1">119 (8.49)</td>
              <td rowspan="1" colspan="1">79 (5.63)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thyroid cancer</td>
              <td rowspan="1" colspan="1">179</td>
              <td rowspan="1" colspan="1">60.27</td>
              <td rowspan="1" colspan="1">57 (31.84)</td>
              <td rowspan="1" colspan="1">122 (68.16)</td>
              <td rowspan="1" colspan="1">62.06 ± 7.56</td>
              <td rowspan="1" colspan="1">27.66 ± 4.70</td>
              <td rowspan="1" colspan="1">16 (8.94)</td>
              <td rowspan="1" colspan="1">6 (3.35)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p><sup>a</sup>Age at diagnosis.</p>
          </fn>
          <fn id="T1TFN2">
            <p>Note: BMI, body mass index.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Subsequently, we applied GWAS analysis to evaluate the prognostic effects of an average of 8 332 476 SNPs across 17 cancer types. The genomic control inflation factor (i.e. lambda; OS/CSS) ranged from 0.77/0.37 for thyroid cancer to 1.12/1.12 for brain cancer, indicating no residual population stratification issues for most cancers. Based on a suggestive genome-wide significance threshold (<italic toggle="yes">P</italic> ≤ 1 × 10<sup>–6</sup>), we identified a total of 1209 OS-associated and 1539 CSS-associated SNPs across 17 cancer types, ranging from 4 loci for lung cancer to 57 loci for lymphoid leukemia among OS-related SNPs, and from 7 loci for colorectal cancer to 54 loci for gastric cancer among CSS-related SNPs (Table <xref rid="tbl2" ref-type="table">2</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1; Table S2</xref>).</p>
      <table-wrap position="float" id="tbl2">
        <label>Table 2.</label>
        <caption>
          <p>Summary of the significant associations of risk factors and circulating biomarkers with cancer survival via Mendelian randomization analysis</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th colspan="6" align="center" rowspan="1">Significant associations with overall survival</th>
              <th colspan="6" align="center" rowspan="1">Significant associations with cancer-specific survival</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">Cancer type</th>
              <th rowspan="1" colspan="1">No. of SNPs</th>
              <th rowspan="1" colspan="1">Lambda</th>
              <th rowspan="1" colspan="1">SNPs<sup>a</sup></th>
              <th rowspan="1" colspan="1">Loci<sup>a</sup></th>
              <th rowspan="1" colspan="1">Phenotypes<sup>b</sup></th>
              <th rowspan="1" colspan="1">Genes<sup>c</sup></th>
              <th rowspan="1" colspan="1">CpG sites<sup>c</sup></th>
              <th rowspan="1" colspan="1">Lambda</th>
              <th rowspan="1" colspan="1">SNPs<sup>a</sup></th>
              <th rowspan="1" colspan="1">Loci<sup>a</sup></th>
              <th rowspan="1" colspan="1">Phenotypes<sup>b</sup></th>
              <th rowspan="1" colspan="1">Genes<sup>c</sup></th>
              <th rowspan="1" colspan="1">CpG sites<sup>c</sup></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Bladder cancer</td>
              <td rowspan="1" colspan="1">8 326 282</td>
              <td rowspan="1" colspan="1">1.03</td>
              <td rowspan="1" colspan="1">34</td>
              <td rowspan="1" colspan="1">23</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">710</td>
              <td rowspan="1" colspan="1">4692</td>
              <td rowspan="1" colspan="1">1.03</td>
              <td rowspan="1" colspan="1">134</td>
              <td rowspan="1" colspan="1">38</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">737</td>
              <td rowspan="1" colspan="1">5017</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Brain cancer</td>
              <td rowspan="1" colspan="1">8 390 743</td>
              <td rowspan="1" colspan="1">1.12</td>
              <td rowspan="1" colspan="1">108</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">847</td>
              <td rowspan="1" colspan="1">5514</td>
              <td rowspan="1" colspan="1">1.12</td>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1">38</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">877</td>
              <td rowspan="1" colspan="1">5574</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">8 338 638</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">99</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">705</td>
              <td rowspan="1" colspan="1">4681</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">29</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">14</td>
              <td rowspan="1" colspan="1">677</td>
              <td rowspan="1" colspan="1">4731</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1">8 334 629</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">5</td>
              <td rowspan="1" colspan="1">692</td>
              <td rowspan="1" colspan="1">4425</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">689</td>
              <td rowspan="1" colspan="1">4301</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Corpus Uteri</td>
              <td rowspan="1" colspan="1">8 360 934</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">161</td>
              <td rowspan="1" colspan="1">35</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">629</td>
              <td rowspan="1" colspan="1">4774</td>
              <td rowspan="1" colspan="1">0.98</td>
              <td rowspan="1" colspan="1">138</td>
              <td rowspan="1" colspan="1">31</td>
              <td rowspan="1" colspan="1">8</td>
              <td rowspan="1" colspan="1">708</td>
              <td rowspan="1" colspan="1">4700</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Esophagus cancer</td>
              <td rowspan="1" colspan="1">8 296 714</td>
              <td rowspan="1" colspan="1">1.07</td>
              <td rowspan="1" colspan="1">47</td>
              <td rowspan="1" colspan="1">36</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">717</td>
              <td rowspan="1" colspan="1">5034</td>
              <td rowspan="1" colspan="1">1.07</td>
              <td rowspan="1" colspan="1">36</td>
              <td rowspan="1" colspan="1">31</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">729</td>
              <td rowspan="1" colspan="1">5198</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gastric cancer</td>
              <td rowspan="1" colspan="1">8 283 963</td>
              <td rowspan="1" colspan="1">1.06</td>
              <td rowspan="1" colspan="1">177</td>
              <td rowspan="1" colspan="1">50</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">743</td>
              <td rowspan="1" colspan="1">4953</td>
              <td rowspan="1" colspan="1">1.07</td>
              <td rowspan="1" colspan="1">270</td>
              <td rowspan="1" colspan="1">54</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">716</td>
              <td rowspan="1" colspan="1">5117</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung cancer</td>
              <td rowspan="1" colspan="1">8 355 227</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">24</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">677</td>
              <td rowspan="1" colspan="1">4518</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">666</td>
              <td rowspan="1" colspan="1">4678</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lymphoid Leukaemia</td>
              <td rowspan="1" colspan="1">8 425 952</td>
              <td rowspan="1" colspan="1">0.97</td>
              <td rowspan="1" colspan="1">98</td>
              <td rowspan="1" colspan="1">57</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">757</td>
              <td rowspan="1" colspan="1">5208</td>
              <td rowspan="1" colspan="1">0.84</td>
              <td rowspan="1" colspan="1">271</td>
              <td rowspan="1" colspan="1">36</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">792</td>
              <td rowspan="1" colspan="1">5142</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Multiple Myeloma</td>
              <td rowspan="1" colspan="1">8 258 091</td>
              <td rowspan="1" colspan="1">1.07</td>
              <td rowspan="1" colspan="1">73</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">680</td>
              <td rowspan="1" colspan="1">4861</td>
              <td rowspan="1" colspan="1">1.05</td>
              <td rowspan="1" colspan="1">104</td>
              <td rowspan="1" colspan="1">41</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">710</td>
              <td rowspan="1" colspan="1">5041</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Oral and pharynx cancer</td>
              <td rowspan="1" colspan="1">8 272 464</td>
              <td rowspan="1" colspan="1">1.05</td>
              <td rowspan="1" colspan="1">99</td>
              <td rowspan="1" colspan="1">30</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">762</td>
              <td rowspan="1" colspan="1">4802</td>
              <td rowspan="1" colspan="1">0.99</td>
              <td rowspan="1" colspan="1">80</td>
              <td rowspan="1" colspan="1">39</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">760</td>
              <td rowspan="1" colspan="1">4819</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Ovarian cancer</td>
              <td rowspan="1" colspan="1">8 351 777</td>
              <td rowspan="1" colspan="1">1.07</td>
              <td rowspan="1" colspan="1">138</td>
              <td rowspan="1" colspan="1">48</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">713</td>
              <td rowspan="1" colspan="1">4978</td>
              <td rowspan="1" colspan="1">1.06</td>
              <td rowspan="1" colspan="1">90</td>
              <td rowspan="1" colspan="1">46</td>
              <td rowspan="1" colspan="1">6</td>
              <td rowspan="1" colspan="1">671</td>
              <td rowspan="1" colspan="1">4856</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic cancer</td>
              <td rowspan="1" colspan="1">8 299 001</td>
              <td rowspan="1" colspan="1">1.07</td>
              <td rowspan="1" colspan="1">29</td>
              <td rowspan="1" colspan="1">22</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">700</td>
              <td rowspan="1" colspan="1">4746</td>
              <td rowspan="1" colspan="1">1.06</td>
              <td rowspan="1" colspan="1">86</td>
              <td rowspan="1" colspan="1">26</td>
              <td rowspan="1" colspan="1">10</td>
              <td rowspan="1" colspan="1">678</td>
              <td rowspan="1" colspan="1">4512</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate cancer</td>
              <td rowspan="1" colspan="1">8 333 069</td>
              <td rowspan="1" colspan="1">1.01</td>
              <td rowspan="1" colspan="1">15</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">703</td>
              <td rowspan="1" colspan="1">4559</td>
              <td rowspan="1" colspan="1">1.00</td>
              <td rowspan="1" colspan="1">29</td>
              <td rowspan="1" colspan="1">9</td>
              <td rowspan="1" colspan="1">18</td>
              <td rowspan="1" colspan="1">719</td>
              <td rowspan="1" colspan="1">4415</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Renal cancer</td>
              <td rowspan="1" colspan="1">8 376 852</td>
              <td rowspan="1" colspan="1">1.03</td>
              <td rowspan="1" colspan="1">32</td>
              <td rowspan="1" colspan="1">17</td>
              <td rowspan="1" colspan="1">11</td>
              <td rowspan="1" colspan="1">754</td>
              <td rowspan="1" colspan="1">5007</td>
              <td rowspan="1" colspan="1">1.03</td>
              <td rowspan="1" colspan="1">91</td>
              <td rowspan="1" colspan="1">24</td>
              <td rowspan="1" colspan="1">6</td>
              <td rowspan="1" colspan="1">728</td>
              <td rowspan="1" colspan="1">4712</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Skin Melanoma</td>
              <td rowspan="1" colspan="1">8 339 443</td>
              <td rowspan="1" colspan="1">0.99</td>
              <td rowspan="1" colspan="1">55</td>
              <td rowspan="1" colspan="1">22</td>
              <td rowspan="1" colspan="1">14</td>
              <td rowspan="1" colspan="1">668</td>
              <td rowspan="1" colspan="1">4350</td>
              <td rowspan="1" colspan="1">0.96</td>
              <td rowspan="1" colspan="1">60</td>
              <td rowspan="1" colspan="1">25</td>
              <td rowspan="1" colspan="1">16</td>
              <td rowspan="1" colspan="1">679</td>
              <td rowspan="1" colspan="1">4635</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Thyroid cancer</td>
              <td rowspan="1" colspan="1">8 308 306</td>
              <td rowspan="1" colspan="1">0.77</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">7</td>
              <td rowspan="1" colspan="1">23</td>
              <td rowspan="1" colspan="1">721</td>
              <td rowspan="1" colspan="1">4977</td>
              <td rowspan="1" colspan="1">0.37</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">451</td>
              <td rowspan="1" colspan="1">2491</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T2TFN1">
            <p><sup>a</sup><italic toggle="yes">P</italic>-value for Cox regression model ≤ 1 × 10<sup>–6</sup>.</p>
          </fn>
          <fn id="T2TFN2">
            <p><sup>b</sup><italic toggle="yes">P</italic>-value for IVW analysis ≤0.05, <italic toggle="yes">P</italic>-value for egger intercept &gt;0.05, and <italic toggle="yes">P</italic>-value for heterogeneity &gt;0.05.</p>
          </fn>
          <fn id="T2TFN3">
            <p><sup>c</sup><italic toggle="yes">P</italic>-value for SMR analysis ≤0.05 and <italic toggle="yes">P</italic>-value for HEIDI &gt;0.05.</p>
          </fn>
          <fn id="T2TFN4">
            <p>Note: SNP, single nucleotide polymorphism; IVW, inverse‐variance weighted; SMR, summary-data-based Mendelian randomization.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="SEC3-2">
      <title>Identification of risk factors and circulating biomarkers associated with cancer survival</title>
      <p>Furthermore, we performed an integrative MR analysis to identify cancer survival-associated risk factors and biomarkers. By combining cancer survival GWAS with PheWAS, eQTL and meQTL datasets, we found an average of 11 phenotypes [ranging from 4 (brain cancer) to 23 (thyroid cancer)], 716 genes [ranging from 629 (corpus uteri) to 847 (brain cancer)] and 4828 CpG sites [ranging from 4350 (skin melanoma) to 5514 (brain cancer)] associated with cancer OS, and an average of 11 phenotypes [ranging from 4 (brain cancer) to 18 (prostate cancer)], 705 genes [ranging from 451 (thyroid cancer) to 877 (brain cancer)] and 4702 CpG sites [ranging from 2491 (thyroid cancer) to 5574 (brain cancer)] associated with cancer CSS (Table <xref rid="tbl2" ref-type="table">2</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Figures S2–S4</xref>). Interestingly, most of the prognostic biomarkers were specific to one cancer type, indicating high heterogeneity across cancers.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Web design and interface</title>
      <p>Finally, we applied the R package <italic toggle="yes">Shiny</italic> to develop a user-friendly database for the findings of the above two-stage analysis [<bold><underline>SU</underline></bold>rvival related cancer <bold><underline>M</underline></bold>ulti-omics database via <bold><underline>ME</underline></bold>ndelian <bold><underline>R</underline></bold>andomization (<bold>SUMMER</bold>): <ext-link xlink:href="http://njmu-edu.cn:3838/SUMMER/" ext-link-type="uri">http://njmu-edu.cn:3838/SUMMER/;</ext-link> Figure <xref rid="F2" ref-type="fig">2</xref>A] with the following four modules: (i) ‘<italic toggle="yes">Survival GWAS Dataset</italic>’ module, to help users browse the association effects of over eight million genetic variants on pan-cancer survival; (ii) ‘<italic toggle="yes">Phenotype-Wide Association Analysis</italic>’ module, to help users browse the causal effects of 150 phenotypes on pan-cancer survival; (iii) ‘<italic toggle="yes">Biomarker-Wide Association Analysis</italic>’ module, to help users browse the causal effects of genome-wide genes and CpG sites on pan-cancer survival and (iv) ‘<italic toggle="yes">Running your data</italic>’ module, to allow users to evaluate their own data on pan-cancer survival. The ‘About’ page provides more details about the function of this database.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Overview of the SUMMER database. (<bold>A</bold>) Advanced search box of the ‘Survival GWAS Dataset’, ‘Phenotype-Wide Association Analysis’ and ‘Biomarker-Wide Association Analysis’ pages. (<bold>B</bold>) Example of a KM plot for rs12798030 and gastric cancer OS, HR and <italic toggle="yes">P</italic> value were from the Cox regression model. (<bold>C</bold>) Example of an MR scatter plot for sleep duration and gastric cancer OS, beta and <italic toggle="yes">P</italic> value were from the IVW method. (<bold>D</bold>) Example of an SMR scatter plot for <italic toggle="yes">HTR6</italic> and colorectal cancer OS, beta and <italic toggle="yes">P</italic> value were from the SMR method. Note: KM, Kaplan–Meier; OS, overall survival; MR, Mendelian randomization; SMR, summary-data-based Mendelian randomization; HR, hazard ratio; IVW, inverse‐variance weighted.</p>
        </caption>
        <graphic xlink:href="gkac677fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-4">
      <title>Data browsing and querying of the four modules</title>
      <p>On the ‘<italic toggle="yes">Survival GWAS Dataset</italic>’ page, when users select a cancer type and enter a batch of SNP IDs or a genetic region, a table with cancer type, chromosome ID, SNP ID, SNP genomic position, SNP alleles (A1: minor/effect allele; A2: major/reference allele), MAF, hazard ratio (HR), standard error (SE) and <italic toggle="yes">P</italic>-value will be built to display the associations of SNPs with cancer survival that includes OS and CSS. Users can download the results by clicking the ‘Download’ button. Besides, users can select one SNP-survival pair and click the ‘Plot’ button, and the diagrams of Kaplan–Meier (KM) plot will be provided to display the associations. For example, our analysis showed that gastric cancer patients with the SNP rs12798030 TG or GG genotypes had shorter OS times than patients with the rs12798030 TT genotype (HR = 1.67, <italic toggle="yes">P</italic> = 2.93 × 10<sup>–7</sup>; <italic toggle="yes">P</italic> for log-rank test = 7.48 × 10<sup>–7</sup>; Figure <xref rid="F2" ref-type="fig">2B</xref>).</p>
      <p>On the ‘<italic toggle="yes">Phenotype-Wide Association Analysis</italic>’ page, when users select a cancer type, a phenotype category (e.g. anthropometric and autoimmune/inflammatory) and a survival type (e.g. OS or CSS), a table with phenotype category, trait, trait ID, cancer type, survival type, MR method, number of IVs, and beta, SE and <italic toggle="yes">P</italic>-value from the MR analysis will be built to display the associations of related phenotypes with cancer survival. Users can download the results by clicking the ‘Download’ button. Besides, users can select one trait-survival pair and click the ‘Plot’ button, and the diagrams of MR scatter plot will be provided to display the associations. For example, we found that sleep duration was associated with an improved OS of gastric cancer (beta<sub>IVW</sub> = –3.53, <italic toggle="yes">P</italic><sub>IVW</sub> = 0.003, <italic toggle="yes">P</italic><sub>egger intercept</sub> = 0.411, <italic toggle="yes">P</italic><sub>IVW heterogeneity</sub> = 0.798; Figure <xref rid="F2" ref-type="fig">2C</xref>).</p>
      <p>On the ‘<italic toggle="yes">Biomarker-Wide Association Analysis</italic>’ page, when users select a cancer type, a biomarker type (e.g. gene expression or CpG site) and a survival type (e.g. OS or CSS), a table with cancer type, survival type, probe ID, probe genomic position, top eQTL/meQTL SNP, top SNP genomic position, MAF from 1000 Genomes EUR population, top SNP-associated eQTL and survival GWAS results (including beta, SE and <italic toggle="yes">P</italic>-value), and beta, SE and <italic toggle="yes">P</italic>-value (including <italic toggle="yes">P</italic><sub>SMR</sub>, <italic toggle="yes">P</italic><sub>multi-SMR</sub> and <italic toggle="yes">P</italic><sub>HEIDI</sub>) from SMR analysis will be built to display the associations of related biomarkers with cancer survival. Users can download the results by clicking the ‘Download’ button. Besides, users can select one biomarker-survival pair and click the ‘Plot’ button, and the diagrams of SMR scatter plot will be provided to display the associations. For example, our analysis showed that higher expression of <italic toggle="yes">HTR6</italic> was associated with poorer OS in colorectal cancer (beta<sub>SMR</sub> = 0.72, <italic toggle="yes">P</italic><sub>SMR</sub> = 2.38 × 10<sup>–4</sup>, <italic toggle="yes">P</italic><sub>multi-SMR</sub> = 0.007, <italic toggle="yes">P</italic><sub>HEIDI</sub> = 0.692; Figure <xref rid="F2" ref-type="fig">2D</xref>).</p>
      <p>On the ‘<italic toggle="yes">Running your data</italic>’ page, this module consists of three steps: (i) selecting a cancer type, a data type (e.g. phenotype or biomarker), a survival type (e.g. OS or CSS), and entering a data name and email address (optional); (ii) uploading your summary statistic data (csv format); and (iii) submitting your data and performing analysis. A table derived from the MR or SMR analysis will be built to display the associations of related phenotypes/biomarkers with cancer survival, which can be downloaded by clicking the ‘Download’ button or received by email. Besides, users can select one pair and click the ‘Plot’ button, and the diagrams of MR/SMR scatter plots will be provided to display the associations.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>DISCUSSION</title>
    <p>In this study, we not only comprehensively evaluated genetic effects at the genome-wide level across pan-cancer prognoses, but also applied MR analysis to identify multiple risk factors and circulating biomarkers relevant to cancer survival. Importantly, we constructed a user-friendly database called SUMMER to help users query, browse, and download corresponding results.</p>
    <p>Cancer mortality remains a major public health concern; therefore, the identification of prognostic risk factors or biomarkers may shed new light on precision oncology (<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>). Especially, circulating biomarkers that are usually detected in peripheral blood have been considered significant tools for monitoring cancer progression and treatment (<xref rid="B26" ref-type="bibr">26</xref>). Until now, it is still difficult for observational studies to estimate causal associations due to the potential confounding bias (<xref rid="B27" ref-type="bibr">27</xref>). Here, we proposed to apply GWAS analysis to calculate the genetic effects on cancer survival at the genome-wide level, and then used the MR analysis framework, a method for causal inference (<xref rid="B28" ref-type="bibr">28</xref>), to construct the SUMMER database for re-evaluating the associations of risk factors and circulating biomarkers with cancer survival. Since SNPs are randomly assorted at meiosis, MR is less likely to be affected by confounding factors compared to conventional observational studies. For example, we found that sleep duration was associated with an improved OS of gastric cancer, which was in agreement with the previously reported MR suggestive results between short sleep duration and increased gastric cancer risk (<xref rid="B29" ref-type="bibr">29</xref>).</p>
    <p>Compared to other germline variants-related databases, our SUMMER database has several strengths. First, this is the first pan-cancer survival-related MR database that integrates survival GWAS with large-scale PheWAS, eQTL and meQTL datasets, to help users evaluate the causal effects of risk factors and circulating biomarkers on predicting cancer prognosis. Second, our database allows users to upload their own PheWAS or QTL summary statistics online. This allows biologists to easily conduct MR analyses for cancer survival without needing to use complex software packages. Third, we constructed a large-scale online pan-cancer survival GWAS dataset with a sufficient sample size (almost 20 000 cancer cases) derived from the well-designed UK Biobank cohort, which can help users easily evaluate the effects of genome-wide variants on cancer survival. Compared to some eQTL databases (e.g. PancanQTL) (<xref rid="B30" ref-type="bibr">30</xref>) with survival-eQTLs function, our database has the following advantages: (i) it is at the genome-wide level, not limited to SNPs with eQTL effects and (ii) it has a larger sample size than that from The Cancer Genome Atlas (TCGA) cohort.</p>
    <p>Some limitations and future directions related to this database should be noted. First, we only included European individuals in our database, and more survival-related data derived from multiple ancestries need to be incorporated in the future. Second, we need to add more cancer GWAS datasets with larger sample sizes and longer follow-up times to further increase the statistical power of our calculation. Third, more risk factors and multi-tissue biomarkers should be further included in our database.</p>
    <p>In summary, we created a comprehensive pan-cancer survival GWAS database underlying MR analysis to evaluate the causal effects of risk factors and circulating biomarkers on cancer prognosis. We believe that SUMMER will greatly expand the understanding of the genetic mechanisms underlying cancer survival for researchers worldwide, further providing an important resource for precision oncology.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC5">
    <title>DATA AVAILABILITY</title>
    <p>The raw genotype and clinical data have been deposited in UK Biobank (<ext-link xlink:href="https://www.ukbiobank.ac.uk/" ext-link-type="uri">https://www.ukbiobank.ac.uk/</ext-link>). The pan-cancer survival results have been deposited in <ext-link xlink:href="http://njmu-edu.cn:3838/SUMMER/" ext-link-type="uri">http://njmu-edu.cn:3838/SUMMER/</ext-link>. All other relevant data will be shared upon reasonable request to the corresponding authors.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkac677_Supplemental_File</label>
      <media xlink:href="gkac677_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We are grateful to the participants and study staff of UK Biobank.</p>
    <p><italic toggle="yes">Author contributions</italic>: M.D. and M.W. are co-responders for this study. Study concept and design: J.X. and M.D. Acquisition of data: M.D. and J.X. Analysis and interpretation of data: J.X., D.G., S.C., S.B. and H.L. Study comment: Z.Z. Drafting of the manuscript: J.X. and M.D.</p>
    <p><italic toggle="yes">Ethics approval</italic>: All participants provided written informed consent prior to data collection. This study was conducted using UK Biobank (Application #45611) and other public resources.</p>
  </ack>
  <sec id="SEC6">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkac677#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>National Natural Science Foundation of China [82173601, 82173603]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine). Funding for open access charge: None.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>L.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>L.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name></person-group><article-title>Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019</article-title>. <source>J. Hematol. Oncol.</source><year>2021</year>; <volume>14</volume>:<fpage>197</fpage>.<pub-id pub-id-type="pmid">34809683</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J.</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bray</surname><given-names>F.</given-names></string-name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>209</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lichtenberg</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hoadley</surname><given-names>K.A.</given-names></string-name>, <string-name><surname>Poisson</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Cherniack</surname><given-names>A.D.</given-names></string-name>, <string-name><surname>Kovatich</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Benz</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>Levine</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>A.V.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title>. <source>Cell</source>. <year>2018</year>; <volume>173</volume>:<fpage>400</fpage>–<lpage>416</lpage>.<pub-id pub-id-type="pmid">29625055</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arnold</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rutherford</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Bardot</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J.</given-names></string-name>, <string-name><surname>Andersson</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Myklebust</surname><given-names>T.A.</given-names></string-name>, <string-name><surname>Tervonen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Thursfield</surname><given-names>V.</given-names></string-name>, <string-name><surname>Ransom</surname><given-names>D.</given-names></string-name>, <string-name><surname>Shack</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study</article-title>. <source>Lancet Oncol.</source><year>2019</year>; <volume>20</volume>:<fpage>1493</fpage>–<lpage>1505</lpage>.<pub-id pub-id-type="pmid">31521509</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sud</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kinnersley</surname><given-names>B.</given-names></string-name>, <string-name><surname>Houlston</surname><given-names>R.S.</given-names></string-name></person-group><article-title>Genome-wide association studies of cancer: current insights and future perspectives</article-title>. <source>Nat. Rev. Cancer</source>. <year>2017</year>; <volume>17</volume>:<fpage>692</fpage>–<lpage>704</lpage>.<pub-id pub-id-type="pmid">29026206</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buniello</surname><given-names>A.</given-names></string-name>, <string-name><surname>MacArthur</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cerezo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Harris</surname><given-names>L.W.</given-names></string-name>, <string-name><surname>Hayhurst</surname><given-names>J.</given-names></string-name>, <string-name><surname>Malangone</surname><given-names>C.</given-names></string-name>, <string-name><surname>McMahon</surname><given-names>A.</given-names></string-name>, <string-name><surname>Morales</surname><given-names>J.</given-names></string-name>, <string-name><surname>Mountjoy</surname><given-names>E.</given-names></string-name>, <string-name><surname>Sollis</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D1005</fpage>–<lpage>D1012</lpage>.<pub-id pub-id-type="pmid">30445434</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Visscher</surname><given-names>P.M.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>McCarthy</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.</given-names></string-name></person-group><article-title>Five years of GWAS discovery</article-title>. <source>Am. J. Hum. Genet.</source><year>2012</year>; <volume>90</volume>:<fpage>7</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">22243964</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gallagher</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Chen-Plotkin</surname><given-names>A.S.</given-names></string-name></person-group><article-title>The Post-GWAS era: from association to function</article-title>. <source>Am. J. Hum. Genet.</source><year>2018</year>; <volume>102</volume>:<fpage>717</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">29727686</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zuber</surname><given-names>V.</given-names></string-name>, <string-name><surname>Grinberg</surname><given-names>N.F.</given-names></string-name>, <string-name><surname>Gill</surname><given-names>D.</given-names></string-name>, <string-name><surname>Manipur</surname><given-names>I.</given-names></string-name>, <string-name><surname>Slob</surname><given-names>E.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wallace</surname><given-names>C.</given-names></string-name>, <string-name><surname>Burgess</surname><given-names>S.</given-names></string-name></person-group><article-title>Combining evidence from mendelian randomization and colocalization: review and comparison of approaches</article-title>. <source>Am. J. Hum. Genet.</source><year>2022</year>; <volume>109</volume>:<fpage>767</fpage>–<lpage>782</lpage>.<pub-id pub-id-type="pmid">35452592</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>G.D.</given-names></string-name>, <string-name><surname>Ebrahim</surname><given-names>S.</given-names></string-name></person-group><article-title>Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title>. <source>Int. J. Epidemiol.</source><year>2003</year>; <volume>32</volume>:<fpage>1</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">12689998</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname><given-names>N.M.</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>M.V.</given-names></string-name>, <string-name><surname>Davey</surname><given-names>S.G.</given-names></string-name></person-group><article-title>Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians</article-title>. <source>BMJ</source>. <year>2018</year>; <volume>362</volume>:<fpage>k601</fpage>.<pub-id pub-id-type="pmid">30002074</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davey</surname><given-names>S.G.</given-names></string-name>, <string-name><surname>Hemani</surname><given-names>G.</given-names></string-name></person-group><article-title>Mendelian randomization: genetic anchors for causal inference in epidemiological studies</article-title>. <source>Hum. Mol. Genet.</source><year>2014</year>; <volume>23</volume>:<fpage>R89</fpage>–<lpage>R98</lpage>.<pub-id pub-id-type="pmid">25064373</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sudlow</surname><given-names>C.</given-names></string-name>, <string-name><surname>Gallacher</surname><given-names>J.</given-names></string-name>, <string-name><surname>Allen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beral</surname><given-names>V.</given-names></string-name>, <string-name><surname>Burton</surname><given-names>P.</given-names></string-name>, <string-name><surname>Danesh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Downey</surname><given-names>P.</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P.</given-names></string-name>, <string-name><surname>Green</surname><given-names>J.</given-names></string-name>, <string-name><surname>Landray</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title>. <source>PLoS Med.</source><year>2015</year>; <volume>12</volume>:<fpage>e1001779</fpage>.<pub-id pub-id-type="pmid">25826379</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ding</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ji</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yin</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetic risk for overall cancer and the benefit of adherence to a healthy lifestyle</article-title>. <source>Cancer Res.</source><year>2021</year>; <volume>81</volume>:<fpage>4618</fpage>–<lpage>4627</lpage>.<pub-id pub-id-type="pmid">34321244</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bycroft</surname><given-names>C.</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>C.</given-names></string-name>, <string-name><surname>Petkova</surname><given-names>D.</given-names></string-name>, <string-name><surname>Band</surname><given-names>G.</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>L.T.</given-names></string-name>, <string-name><surname>Sharp</surname><given-names>K.</given-names></string-name>, <string-name><surname>Motyer</surname><given-names>A.</given-names></string-name>, <string-name><surname>Vukcevic</surname><given-names>D.</given-names></string-name>, <string-name><surname>Delaneau</surname><given-names>O.</given-names></string-name>, <string-name><surname>O’Connell</surname><given-names>J</given-names></string-name><etal>et al</etal>.</person-group><article-title>The UK biobank resource with deep phenotyping and genomic data</article-title>. <source>Nature</source>. <year>2018</year>; <volume>562</volume>:<fpage>203</fpage>–<lpage>209</lpage>.<pub-id pub-id-type="pmid">30305743</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lyon</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Elsworth</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gaunt</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Hemani</surname><given-names>G.</given-names></string-name>, <string-name><surname>Marcora</surname><given-names>E.</given-names></string-name></person-group><article-title>The variant call format provides efficient and robust storage of GWAS summary statistics</article-title>. <source>Genome Biol.</source><year>2021</year>; <volume>22</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">33441155</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hemani</surname><given-names>G.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Elsworth</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wade</surname><given-names>K.H.</given-names></string-name>, <string-name><surname>Haberland</surname><given-names>V.</given-names></string-name>, <string-name><surname>Baird</surname><given-names>D.</given-names></string-name>, <string-name><surname>Laurin</surname><given-names>C.</given-names></string-name>, <string-name><surname>Burgess</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bowden</surname><given-names>J.</given-names></string-name>, <string-name><surname>Langdon</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The MR-base platform supports systematic causal inference across the human phenome</article-title>. <source>ELIFE</source>. <year>2018</year>; <volume>7</volume>:<fpage>e34408</fpage>.<pub-id pub-id-type="pmid">29846171</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prince</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>R.E.</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>T.G.</given-names></string-name></person-group><article-title>Integrative multiomics analysis highlights immune-cell regulatory mechanisms and shared genetic architecture for 14 immune-associated diseases and cancer outcomes</article-title>. <source>Am. J. Hum. Genet.</source><year>2021</year>; <volume>108</volume>:<fpage>2259</fpage>–<lpage>2270</lpage>.<pub-id pub-id-type="pmid">34741802</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burgess</surname><given-names>S.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>S.G.</given-names></string-name></person-group><article-title>Interpreting findings from mendelian randomization using the MR-Egger method</article-title>. <source>Eur. J. Epidemiol.</source><year>2017</year>; <volume>32</volume>:<fpage>377</fpage>–<lpage>389</lpage>.<pub-id pub-id-type="pmid">28527048</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vosa</surname><given-names>U.</given-names></string-name>, <string-name><surname>Claringbould</surname><given-names>A.</given-names></string-name>, <string-name><surname>Westra</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Bonder</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Deelen</surname><given-names>P.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>B.</given-names></string-name>, <string-name><surname>Kirsten</surname><given-names>H.</given-names></string-name>, <string-name><surname>Saha</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kreuzhuber</surname><given-names>R.</given-names></string-name>, <string-name><surname>Yazar</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>1300</fpage>–<lpage>1310</lpage>.<pub-id pub-id-type="pmid">34475573</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hannon</surname><given-names>E.</given-names></string-name>, <string-name><surname>Gorrie-Stone</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Smart</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Burrage</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Kumari</surname><given-names>M.</given-names></string-name>, <string-name><surname>Schalkwyk</surname><given-names>L.C.</given-names></string-name>, <string-name><surname>Mill</surname><given-names>J.</given-names></string-name></person-group><article-title>Leveraging DNA-Methylation quantitative-trait loci to characterize the relationship between methylomic variation, gene expression, and complex traits</article-title>. <source>Am. J. Hum. Genet.</source><year>2018</year>; <volume>103</volume>:<fpage>654</fpage>–<lpage>665</lpage>.<pub-id pub-id-type="pmid">30401456</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Bakshi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Powell</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Montgomery</surname><given-names>G.W.</given-names></string-name>, <string-name><surname>Goddard</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Wray</surname><given-names>N.R.</given-names></string-name>, <string-name><surname>Visscher</surname><given-names>P.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets</article-title>. <source>Nat. Genet.</source><year>2016</year>; <volume>48</volume>:<fpage>481</fpage>–<lpage>487</lpage>.<pub-id pub-id-type="pmid">27019110</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Qi</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lloyd-Jones</surname><given-names>L.R.</given-names></string-name>, <string-name><surname>Marioni</surname><given-names>R.E.</given-names></string-name>, <string-name><surname>Martin</surname><given-names>N.G.</given-names></string-name>, <string-name><surname>Montgomery</surname><given-names>G.W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>918</fpage>.<pub-id pub-id-type="pmid">29500431</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Sheltzer</surname><given-names>J.M.</given-names></string-name></person-group><article-title>Genome-wide identification and analysis of prognostic features in human cancers</article-title>. <source>Cell Rep.</source><year>2022</year>; <volume>38</volume>:<fpage>110569</fpage>.<pub-id pub-id-type="pmid">35354049</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mehta</surname><given-names>S.</given-names></string-name>, <string-name><surname>Shelling</surname><given-names>A.</given-names></string-name>, <string-name><surname>Muthukaruppan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lasham</surname><given-names>A.</given-names></string-name>, <string-name><surname>Blenkiron</surname><given-names>C.</given-names></string-name>, <string-name><surname>Laking</surname><given-names>G.</given-names></string-name>, <string-name><surname>Print</surname><given-names>C.</given-names></string-name></person-group><article-title>Predictive and prognostic molecular markers for cancer medicine</article-title>. <source>Ther. Adv. Med. Oncol.</source><year>2010</year>; <volume>2</volume>:<fpage>125</fpage>–<lpage>148</lpage>.<pub-id pub-id-type="pmid">21789130</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rapisuwon</surname><given-names>S.</given-names></string-name>, <string-name><surname>Vietsch</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Wellstein</surname><given-names>A.</given-names></string-name></person-group><article-title>Circulating biomarkers to monitor cancer progression and treatment</article-title>. <source>Comput. Struct. Biotechnol. J.</source><year>2016</year>; <volume>14</volume>:<fpage>211</fpage>–<lpage>222</lpage>.<pub-id pub-id-type="pmid">27358717</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meuli</surname><given-names>L.</given-names></string-name>, <string-name><surname>Dick</surname><given-names>F.</given-names></string-name></person-group><article-title>Understanding confounding in observational studies</article-title>. <source>Eur. J. Vasc. Endovasc. Surg.</source><year>2018</year>; <volume>55</volume>:<fpage>737</fpage>.<pub-id pub-id-type="pmid">29526654</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sekula</surname><given-names>P.</given-names></string-name>, <string-name><surname>Del</surname><given-names>G.M.F.</given-names></string-name>, <string-name><surname>Pattaro</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kottgen</surname><given-names>A.</given-names></string-name></person-group><article-title>Mendelian randomization as an approach to assess causality using observational data</article-title>. <source>J. Am. Soc. Nephrol.</source><year>2016</year>; <volume>27</volume>:<fpage>3253</fpage>–<lpage>3265</lpage>.<pub-id pub-id-type="pmid">27486138</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Titova</surname><given-names>O.E.</given-names></string-name>, <string-name><surname>Michaelsson</surname><given-names>K.</given-names></string-name>, <string-name><surname>Vithayathil</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mason</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Kar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Burgess</surname><given-names>S.</given-names></string-name>, <string-name><surname>Larsson</surname><given-names>S.C.</given-names></string-name></person-group><article-title>Sleep duration and risk of overall and 22 site-specific cancers: a mendelian randomization study</article-title>. <source>Int. J. Cancer</source>. <year>2021</year>; <volume>148</volume>:<fpage>914</fpage>–<lpage>920</lpage>.<pub-id pub-id-type="pmid">32895918</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Xiang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>R.</given-names></string-name>, <string-name><surname>Diao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D971</fpage>–<lpage>D976</lpage>.<pub-id pub-id-type="pmid">29036324</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
